Established as a private limited company in 1987, Fredun Pharmaceuticals (FPL) underwent conversion to a public limited company in March 1994. The company was founded by Nariman Medhora and Daulat N Medhora. Initially, the promoters established D N Pharma, a proprietary firm, dedicated to manufacturing and exporting pharmaceutical formulations. By 1993, operations at D N Pharma were gradually phased out to transition the business to FPL. FPL boasts a diversified portfolio ranging from Formulations to Diagnostics to Consultancy. Offering a unique array of products, from specialized formulations and anti-diabetics to cutting-edge antiretroviral and anti-hypertensive products, FPL supplies finished formulations to over 42 countries worldwide. It maintains partnerships with numerous governments worldwide, acknowledging the necessity of robust and consistent healthcare systems.
The company's inception aimed at providing manufacturing and marketing facilities for various pharmaceutical formulations such as tablets, capsules, dry syrups, and ointments. Subsequently, it established a formulation unit in Palghar (Thane District), Maharashtra, which commenced commercial production in August 1994. FPL has been engaged in manufacturing operations under loan license arrangements for renowned pharmaceutical companies like Cipla. Additionally, it manufactures for select merchant exporters, including Merind. In April 1996, the company conducted a public issue to register its products in the overseas market for exports, to partially fund the expansion of its business activities, and to alleviate the interest burden from one of its term loans and unsecured loans.
The company anticipates a revival in turnover with significant export orders on hand. It is also in the process of registering various drugs with different countries such as Nepal, Tanzania, Uganda, and Sri Lanka. In 2013, the company launched 36 new products and filed registrations for 60 new products. It introduced a herbal dietary supplement in Africa. In 2015, three new granulation departments were added to the existing two. In 2023, FPL launched 19 new products under the Cosmeceuticals OEM Division and introduced 14 new products in the pet pharmaceuticals line, with another 36 in development. Furthermore, it launched 16 products in the Pet Treat and Nutritional Supplement category.
The company's inception aimed at providing manufacturing and marketing facilities for various pharmaceutical formulations such as tablets, capsules, dry syrups, and ointments. Subsequently, it established a formulation unit in Palghar (Thane District), Maharashtra, which commenced commercial production in August 1994. FPL has been engaged in manufacturing operations under loan license arrangements for renowned pharmaceutical companies like Cipla. Additionally, it manufactures for select merchant exporters, including Merind. In April 1996, the company conducted a public issue to register its products in the overseas market for exports, to partially fund the expansion of its business activities, and to alleviate the interest burden from one of its term loans and unsecured loans.
The company anticipates a revival in turnover with significant export orders on hand. It is also in the process of registering various drugs with different countries such as Nepal, Tanzania, Uganda, and Sri Lanka. In 2013, the company launched 36 new products and filed registrations for 60 new products. It introduced a herbal dietary supplement in Africa. In 2015, three new granulation departments were added to the existing two. In 2023, FPL launched 19 new products under the Cosmeceuticals OEM Division and introduced 14 new products in the pet pharmaceuticals line, with another 36 in development. Furthermore, it launched 16 products in the Pet Treat and Nutritional Supplement category.
